Laboratory:Akiruno
- TOP
- gene-related test
- genetic tests for malignant tumor (solid tumor)
- AmoyDx lung cancer multi-panel 7-gene (12-24 months)
Laboratory:Akiruno
○AmoyDx lung cancer multi-panel 7-gene (12-24 months)
CODE:00P45 6
-
TEST NAME
SPECIMEN
REQUIREMENT
(mL) CONTAINER CAP COLOR STORE
TEMPERATURE
(STABILITY) TURNAROUND
TIME (DAY) METHODOLOGY REFERENCE RANGE
(UNIT) -
AmoyDx lung cancer multi-panel 7-gene (12-24 months)
Unstained specimen slide
7 to 10 sheets
thickness 5μm
Z10
4-7 PCR (real-time PCR, RT-PCR (real-time PCR)
COMMENT
The purpose of this test is to analyze BRAFV600E mutations, EGFR gene mutations, ALK fusion genes, ROS1 fusion genes, MET gene exon 14 skipping mutations, KRASG12C gene mutations, and RET fusion genes in genomic DNA and RNA extracted from cancer tissue, and to determine whether or not drugs listed in the separate table are suitable for non-small cell lung cancer patients.
The required percentage of tumor cells for the test is 20% or more (recommended 30% or more). Please see below for points to note when submitting unstained specimen slides.
Please avoid making duplicate requests with other items. This test method is more susceptible to contamination, so please handle specimens with care.
When requesting this test, be sure to also request the nucleic acid extraction item (item code No.0M951 3).
*When submitting unstained specimen slides
-Immediately immerse the collected tissue in 10% neutral buffer formalin solution and fix it (fixation time is 6 to 4 (We recommend leaving the slide for approximately 8 hours.) When submitting the slide, please prepare serial sections at a thickness of 5 μm from the formalin-fixed paraffin-embedded tissue block.
-Unstained slides must be histopathologically evaluated and confirmed that they contain the required percentage of tumor cells for the test (the percentage of tumor cells among all cells in the specimen). If the required percentage is not met, please mark the tumor cell area from the back of the unstained slide. If the slide is submitted without marking, macrodissection will not be possible, resulting in false negative results. Please note that this may affect the quality of the results.
- Please submit FFPE tissue prepared within the last 12 to 24 months.
- Since nucleic acids in unstained specimen slides are fragmented due to formalin fixation of the tissue, analysis may be impossible depending on the type and composition of the fixative, fixation time, and storage conditions of the specimen after fixation. Please note that biopsy materials in particular often contain very small amounts of specimens, and there may be cases where the tissue fragments on the paraffin sections are very small or may not contain tumor cells.
CONTAINER
Z10 旧容器記号 t 30
[オブジェクトケース]
プレパラート (スライドグラス)
貯蔵方法:室温
supplementary information
対象遺伝子変異等と関連する医薬品および適応がん腫
遺伝子変異等 | がん腫 | 関連する医薬品 |
---|---|---|
BRAF V600E変異 | 非小細胞肺癌 | ダブラフェニブメシル酸塩及びトラメチニブジメチルスルホキシド付加物の併用投与 |
EGFR遺伝子変異 | ゲフィチニブ、エルロチニブ塩酸塩、アファチニブマレイン酸塩、オシメルチニブメシル酸塩 | |
ALK融合遺伝子 | クリゾチニブ、アレクチニブ塩酸塩、ブリグチニブ | |
ROS1融合遺伝子 | クリゾチニブ、エヌトレクチニブ | |
MET ex14スキッピング変異 | テポチニブ塩酸塩水和物 | |
KRAS G12C遺伝子変異 | ソトラシブ | |
RET融合遺伝子 | セルペルカチニブ |